Laboratory of Cancer Genetics, School of Medical Sciences, State University of Campinas, Campinas 13083-970, SP, Brazil.
Department of Anesthesiology, Oncology and Radiology, School of Medical Sciences, State University of Campinas, Campinas 13083-970, SP, Brazil.
Int J Mol Sci. 2024 Nov 17;25(22):12327. doi: 10.3390/ijms252212327.
This study aimed to verify whether germline single nucleotide variants (SNV) in gene, c.-1765C>T, c.-1661A>G, c.-1577G>A, and c.-1478G>A, influence the risk, clinicopathological aspects, and survival of patients with CM, as well as its functional consequences. A total of 432 patients with CM and 504 controls were evaluated. genotypes were identified by real-time polymerase chain reaction (RT-PCR) and expression of by quantitative PCR (qPCR) and luciferase assay. Cell cycle, proliferation, apoptosis/necrosis, and migration analyses were performed in SK-MEL-28 and A-375 cell lines modified to present homozygous ancestral or variant genotypes by CRISPR technique. Individuals with the c.-1577 AA genotype and the combined c.-1577 and c.-1478 AA + AA genotypes were at 1.60- and 3.12-fold higher risk of developing CM, respectively. The c.-1577 AA genotype was seen as an independent predictor of worse event-free survival and was also associated with higher gene expression, higher cell proliferation, lower cell apoptosis, and higher cell migration. Our data present, for the first time, evidence that c.-1577G>A alters the risk and clinical aspects of CM treated with conventional procedures and may be used for selecting individuals for tumor prevention and patients for distinct treatment.
本研究旨在验证基因中的种系单核苷酸变异(SNV)c.-1765C>T、c.-1661A>G、c.-1577G>A 和 c.-1478G>A 是否会影响 CM 患者的风险、临床病理特征和生存,以及其功能后果。共评估了 432 名 CM 患者和 504 名对照者。通过实时聚合酶链反应(RT-PCR)鉴定基因型,通过定量 PCR(qPCR)和荧光素酶测定法鉴定 基因的表达。通过 CRISPR 技术使 SK-MEL-28 和 A-375 细胞系呈现纯合原始或变异基因型,然后进行细胞周期、增殖、凋亡/坏死和迁移分析。具有 c.-1577 AA 基因型和联合的 c.-1577 和 c.-1478 AA + AA 基因型的个体患 CM 的风险分别增加了 1.60 倍和 3.12 倍。 c.-1577 AA 基因型被视为 CM 无事件生存的独立预测因子,并且还与更高的基因表达、更高的细胞增殖、更低的细胞凋亡和更高的细胞迁移相关。我们的数据首次提供了证据,表明 c.-1577G>A 改变了常规治疗的 CM 的风险和临床特征,并且可以用于选择个体进行肿瘤预防和选择不同的治疗患者。